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Introduction
Over the past several decades the United States has been experiencing an epidemic of
prescription and non-prescription opioid use. The WHO World Drug Report found that in 2014
there were an estimated 33 million opioid users world-wide, including about 15.6 million users
of non-medical prescription opioids and 17.4 million opium and heroin users1. In the USA,
approximately 2 million people had a substance use disorder involving prescription opioids in
2015, while 591,000 had a heroin use disorder2. This same year over 20,000 Americans died of a
prescription opioid overdose and nearly 13,000 died of a heroin overdose. These rates have
increased rapidly in recent years; from 1999 to 2014 they nearly tripled, and from 2014 to 2015
overdose deaths due to prescription opioids increased by 72.2%, while heroin overdoses
increased by 20.6%3. These increased rates of heroin and prescription opioid use and overdose
have been found throughout the country, though the north-eastern region has the highest ageadjusted rate of 16.1 per 10,000 as of 2016 4. Connecticut is no exception to this trend – from
2014-15 it was second only to New York state in percent-increase of deaths due to fentanyl, and
deaths due to opioids generally grew by about 27% in that same period to 11.3 per 100,0005.
Other than alcohol dependence, opioid dependence had the highest absolute Disability
Adjusted Life Years (DALYs) of all other measured drug use disorders, accounting for 46% of
all substance-abuse-related DALYs excluding alcohol. This is partially due to the fact that opioid
dependence was given a higher disability weight (.64) than all other substance use disorders, and
was considered to be closer to disorders such as severe epilepsy (.66), severe multiple sclerosis
(.70), or acute schizophrenia (.76), suggesting severe disability associated with the disorder6. The
Council for Economic Advisors estimated the total economic impact of the opioid epidemic in
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2015, including premature death, incarceration, and other non-fatal costs, at $504 Billion7 - about
2.8% of the national GDP.
It is important to recognize that the majority of those with opioid use disorder are not in
treatment. One study found that about 26% of patients with opioid use disorder had ever attended
an alcohol or drug treatment program, while only 19% had attended an opioid-specific treatment
program8. One analysis of treatment utilization nationally found that about 77% of US states
reported that their opioid treatment programs were operating at 80% capacity or above,
suggesting that lack of access to treatment and related service options might present a barrier to
entry for many patients seeking help9. Additional evidence suggests that early entry to treatment
might be beneficial for long term remittance of opioid use as duration of opioid use/dependence
has been associated with increased likelihood of relapse to opioid use10. One survey found that
more patients with substance use disorder were willing to enter treatment from their primary care
provider than from a drug treatment program11, and this appears to be reflected in patient contact
with healthcare providers – the majority of substance using patients encounter a primary care
physician long before they begin specialized drug treatment12.
Background
As in many public health crises, primary care providers are serving as the front line
against the opioid epidemic in the US13. Implementation of programs such as the Screening,
Brief Intervention, and Referral to Treatment (SBIRT) for the identification and referral of
opioid users in the primary setting is often discussed and promoted as one way in which these
providers can better serve in this role, but implementation appears to be severely lagging behind
the need for these services14. Many barriers to implementation have been identified, but another
complimentary approach is to demonstrate and evaluate the utility of the screening tools used,
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such as the Alcohol, Smoking, and Substance Involvement Screening Tool (ASSIST) for opioid
use within the primary care setting. The ASSIST is one of several possible screening tools which
can be used for an SBIRT program.
The ASSIST was developed in the early 2000s by the World Health Organization in order
to serve as a screening tool for substance use (including tobacco and alcohol) internationally. It
was designed to be applicable across international and cultural borders, capturing differing
patterns of substance use across these boundaries, and has been translated into many languages.
The screening tool was also intended to meet multiple objectives, such as case finding and risk
factor screening. These features were found specifically limited in existing screening tools, and
the development of the ASSIST was intended to address these concerns while improving
sensitivity and specificity15.
The ASSIST underwent extensive testing and redevelopment over a period of several
years, and is now in its third revision. Currently the ASSIST addresses 11 substance categories;
tobacco, alcohol, marijuana, cocaine or crack, prescription stimulants, methamphetamine,
inhalants, sedatives or sleeping pills, hallucinogenic/psychedelics, non-medical use of
prescription pain medication, and heroin, as well as another option for substance not fitting into
one of these categories. The ASSIST is administered by a provider and begins by asking about
the lifetime use of each of these categories. For each substance the respondent reports use during
their lifetime, seven follow-up questions are asked. Three of these questions pertain to the
respondent’s lifetime use of this substance; the subject is asked if they have ever used any drug
by injection, if a friend or relative has ever expressed concern about their use of the particular
drug being asked about, and if the respondent has ever tried and failed to control their use of that
drug. The remaining four questions pertain only to the past three months; they ask specifically
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about the respondent’s frequency of use during this period, how often they have had a desire to
use the substance, how often the use of that substance has led to problems in their life (health,
social, legal, or financial problems), and how often they feel that they have failed to do what was
expected of them because of their drug use. From the answers to these questions the provider
may easily calculate a substance-specific score which indicates a risk category for that substance.
These score categories indicate the risk of health and other problems related to the respondent’s
use of that substance. In regards to its use within this SBIRT program, a ‘low’ score simply
indicates feedback to the respondent, a moderate-low score indicates a brief intervention, a
moderate-high score indicates a brief intervention as well as a brief treatment, and a high score
indicates a brief intervention and referral to treatment16.
Following its initial development the ASSIST has been the subject of several validation
studies. One study involving 1047 participants across multiple sites in seven countries examined
the ASSIST for concurrent, construct and discriminative validity. In comparison with existing
similar screening tools the ASSIST score had significant correlation. Furthermore these scores
were associated with known substance abuse risk factors. Discriminative validity varied by
substance and identification of use/abuse versus abuse/dependence (generally discriminative
validity was higher in the case of use/abuse than dependence), but was generally found to be
high with most AUC values above .75 and good values for sensitivity and specificity17. Other
studies have found similar results18 19 20 21.
The SBIRT model is older and more studied than the ASSIST screening tool, but
research regarding its efficacy remains incomplete. Several studies have examined the efficacy
of the referral to treatment portion of the model with mixed results22 23. Most of these studies
have focused on alcohol and comparatively few of them have used the ASSIST for screening
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purposes. One study evaluated an implementation of SBIRT using the ASSIST and found that
those who had received SBIRT had an increased utilization of outpatient services and a decrease
of inpatient services, suggesting increased treatment utilization overall, but these results were not
substance-specific and the ASSIST score itself was not included as a predictor for treatment
utilization 24. Another study did not utilize the ASSIST but did examine efficacy for individual
substance categories for a SBIRT project conducted in the ED setting – here it was found that
those who went on to treatment may have had higher drug use severity scores generally, but
there were insufficient heroin-using participants to establish this result more specifically for
opioid users25. Currently no studies have evaluated the efficacy of an SBIRT program in the
primary care setting for referral of opioid users to treatment, and no studies have evaluated the
ASSIST opioid-specific score as a predictor of substance use treatment utilization.
The aim of this analysis is to evaluate the utility of the ASSIST for use in a primary care
setting in three major ways.


First we will investigate the validity of the ASSIST for identification of substance
users by comparing patient responses to the ASSIST with matched clinical
records. This will allow us to evaluate the accuracy of the information provided to
the primary care provider when a patient does not indicate a history of opioid use
(referred to as a negative screen for opioids).



Second, we will determine the utility of the ASSIST substance-specific score as
an indicator of prior treatment episodes. This will establish the relationship
between substance use risk severity and treatment utilization.



Third, we will evaluate the efficacy of the ASSIST substance-specific score for
prediction of future substance use treatment utilization within one year. If the

Adam Chess | Page 6

ASSIST score can be used effectively as a predictor of treatment, providers
utilizing this tool could gain insight into their patients’ longer-term trajectory as
well as their potential receptivity towards referral to treatment.
Methods
This study utilized administrative and screening data sources to evaluate the ASSIST as
an indicator of prior substance use treatment utilization, and as a predictor of future one-year
entry to treatment for alcohol, opioid, and crack/cocaine users. Data was obtained from the
Connecticut SBIRT administrative database . Patient SBIRT records were matched with
administrative data from the Connecticut Department of Mental Health and Addiction Services
(DMHAS) DDaP records system. Data were collected from screenings completed from
01/01/2012 to 12/31/2015 including 31,744 records of 28,637 individual study subjects, 25,540
of whom were sampled for this study, having been identified for positive lifetime use of alcohol,
opioids, or crack/cocaine. Initial subjects were sampled from the population using random
sampling, drawing on patients visiting a community health center within the study period who
elected to participate in the study. ‘Positive lifetime use’ here indicates one of the following
conditions were true for the study subject;
1. The subject self-identified as having ever used non-medical use of heroin, prescription
opioids, alcohol, cocaine, or crack at least once within their lifetime.
2. The subject had a medical diagnosis indicating use of heroin, prescription opioids,
alcohol, cocaine, or crack at least once within their lifetime.
3. The subject had a clinical indicator, such as ‘drug of choice’, ‘primary drug’, ‘secondary
drug’, or ‘tertiary drug’, indicating use of heroin, prescription opioids, alcohol, cocaine,
or crack at least once within their lifetime.
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CT DMHAS was awarded a five-year grant from the federal Substance Abuse and
Mental Health Services Administration (SAMHSA) in 2011 to establish the CT SBIRT program.
The goals of this program were to introduce SBIRT services to provider settings such as
community health centers, support brief interventions for substance and alcohol use, improve
patient linkage to treatment programs, and to find ways to improve access to substance and
alcohol use treatment. The University of Connecticut Health Center (UCHC) conducted a
program evaluation to assess these goals and to monitor the implementation of the program.
UCHC established the SBIRT training institute and trained ten full-time-equivalent health
educators to serve ten community health centers in Connecticut. The role of these Health
Educators was to understand and implement the SBIRT program in a community health center
setting while collecting data for evaluation of the program.
Health educators (HEs) underwent training for a period between seven days to one month
depending on prior experience. These educators were provided ongoing coaching and evaluation,
and were eventually certified in SBIRT implementation. Health educators who completed their
training were expected to understand the roles of all services provided by CT SBIRT and all
available services as related to substance use. Educators were trained extensively in motivational
interviewing practice and theory (part of the brief intervention protocol), as well as common
conditions and challenges in health centers, and SBIRT protocols for screening, brief
intervention, and referral to treatment. Additional training focused on establishing an
understanding of patient confidentiality issues, HIPAA regulations, ethical requirements, and
elements of cultural proficiency. HEs were expected to ensure that data relating to the
Government Performance and Results Act (GPRA) were processed properly, and these educators
were also informed of the requirements and importance of collecting this data.
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Health educators worked in ten Connecticut community health centers that participated in
the CT SBIRT program. Community health centers often serve underserved and low-income
people. These populations tend to be racially and ethnically diverse, and a relatively high
proportion of their population are uninsured. The health centers which opted to participate in the
SBIRT program were located across Connecticut. Table 1 shows labels for individual
community health centers as well as the size of the sample drawn from that health center and
percentage of the total sample. Some portions of Connecticut may have been over or under
represented in this sample based on the distribution of the health center locations.
The populations served by community health centers, especially those uninsured or
Medicaid-eligible, may have an elevated risk of substance use disorder. The CT SBIRT program
sought to utilize community health centers because of the opportunity to focus on these high-risk
individuals, while also demonstrating the implementation of a screening and brief intervention
program in a primary care setting.
Community Health
Center Label
A
B
C
D
E
F
G
H
I
J
TOTAL

Patients with positive lifetime use of Opioids,
Alcohol,
or Crack/Cocaine
6657
4053
2691
2904
2288
1864
1624
1424
1091
942
25540

Percent of
sample
26%
16%
11%
11%
9%
7%
6%
6%
4%
4%

Table 1-Participating Community Health Centers Sampled with Location

Screening and intervention procedures were established in these ten CHCs, to be
primarily implemented by trained HE staff. All randomly selected patients presenting to the CHC
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would be introduced to the HE as a member of the patient’s care team. The HE would establish
rapport with the patient and would also record relevant demographic data. Using the ASSIST, the
patient would be screened for alcohol and substance use, and the HE would calculate the
patient’s substance-specific score. The ASSIST was chosen as the screening tool for this
program because of its high discriminant validity, and its capacity to assess a wide range of
substance categories. The ASSIST assesses the following substance categories; tobacco, alcohol,
marijuana, cocaine or crack, prescription stimulants, methamphetamine, inhalants, sedatives or
sleeping pills, hallucinogens or psychedelics, prescription pain medication (non-medical use),
heroin, or other drugs.
The version of the ASSIST utilized for this program asks the subject seven questions and
may be found in Appendix A. Three of these questions pertain to the lifetime substance use of
the subject; they ask if the subject has ever used the substance, if their friends or relatives have
ever expressed concern about their use of the substance, and if they had ever tried and failed to
cut down or stop using the substance. These questions allow the user to specify if these occurred
within the past three months or not. The four remaining questions address the subject’s use of the
substance within the past three months specifically, and allow the user to specify frequency
(‘daily’, ‘weekly’, ‘monthly’, etc.). These questions ask the user about frequency of substance
use, frequency of having a strong desire or urge to use the substance, how often the use of this
substance has led to social, health related, or financial problems, and finally, how frequently use
of the substance has led the user to fail to do what was normally expected of them. All of these
questions are asked for each substance for which the user reports positive lifetime use. All of the
responses to these questions have an associated weighted score, and the calculation of the
substance-specific score is the summation of all of the weighted scores for each response
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pertaining to that substance for the subject, with the exception of the question pertaining to
lifetime ever-use. Under the rubric of the CT SBIRT program these scores are then categorized
into one of four categories; ‘low’, ‘moderate-low’, ‘moderate-high’ or ‘high’ levels of risk for
developing health and other problems related to current patterns of use. These cutoffs varied by
substance. A score for alcohol below 11 points was considered ‘low’, between 11 and 19 was
‘moderate-low’, 20-26 was considered moderate-high, and anything 27 or higher was considered
‘high’. Drug categorizations for ‘moderate-high’ and ‘high’ score categories were the same, but a
score below 4 was considered ‘low’ for drug use, with a score between 4 and 19 being
‘moderate-low’. The ASSIST Lifetime score was not used by the HE within their assessment but
was used for this study. The ASSIST Lifetime score is calculated by assigning 3 points for every
substance category (including tobacco and alcohol) for which the respondent reports lifetime
ever use. The ASSIST lifetime score can be viewed as an indicator of lifetime poly-substance
use.
Once the HE obtained the substance-specific score for the subject, he/she proceeded with
the SBIRT procedure according to the score category of the user. If the user scored in the ‘low’
category for any substance the HE explained the results and encouraged the subject to continue
to pursue positive health choices. If the patient scored in the ‘moderate-low’ category the HE
offered the patient the opportunity to receive a brief intervention relating to this substance use. If
the patient accepted this offer, the HE would provide a brief 10-15 intervention using a
counseling style called motivational interviewing. This brief intervention would involve
coaching the subject through a review of strategies for change, and literature would also be
provided relating to the effects of drugs and alcohol use. One possible limitation of this study is
that subjects at different levels of motivation could have received different interventions,
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depending on their willingness to receive these interventions. If the patient scored in the
moderate-high category, or if they requested it, the subject would also receive a verbal
recommendation for a brief treatment, or a referral to a substance use treatment provider. If the
subject scored in the high-risk category for development of health and other problems related to
current patterns of use, the HE provided feedback and referred the patient to a specialty
substance use treatment provider. It is a recognized limitation of this study that those in the
‘moderate-high’ and ‘high’ categories were likely to have been referred to substance use
treatment, and that this complicates the evaluation of the relationship between ASSIST score and
one-year entry to treatment. The results of this study are evaluated with this limitation in mind.
The data for this study consists of a sample of 25,540 patients screened via the CT
SBIRT program who were positively identified via the ASSIST or other clinical measures for
lifetime ever-use of alcohol, cocaine/crack, or heroin/prescription pain medication, screened
between 01/01/2012 and 12/31/2015. The initial screened population included all adults ages 18
and older who presented at one of the ten health centers within these dates. Through use of the
LinkKing software package these records were matched to the CT DMHAS DDaP database.
Linking these records allowed clinical information, including administrative records of treatment
utilization, to be linked to responses on the ASSIST. Records were linked on the basis of patient
names, date of birth, and social security number when available. None of this personally
identifiable information was contained in the final dataset. This DMHAS database included
demographic information as well as diagnostic records, clinical measures, and substance abuse
treatment utilization records for anyone admitted to a licensed substance use treatment facility in
Connecticut. Specifically, this database included admission and discharge dates and records for
all Connecticut mental health and substance use treatment patients, including inpatient,
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outpatient, and methadone treatment programs. All screening response data was contained in the
CT SBIRT database which itself also included demographic data and records of treatments and
services provided.
Statistical Analyses
A number of statistical modeling methods were used for this study. All reported p values
throughout the study have been adjusted for multiple comparisons by the Benjamini and
Hochberg False Discovery Rate controlling procedure, and all power analyses were conducted
by post-hoc Monte-Carlo simulation. Throughout this study, all logistic and Poisson regression
models were evaluated for multicollinearity using VIF analysis. Few VIF statistics were found to
be below 2.5, indicating low to moderate multicollinearity, but in cases where VIF statistics were
higher than 2.5 one of the collinear variables was removed from the model. All adjusted pseudoR2 values were calculated as McFadden’s adjusted R2 statistics.
Analyses focused on three distinct aims;
1. Describing the characteristics of the sample, including the capacity of the ASSIST to
identify substance users, as well as related sample characteristics.
2. Assessing the relationship between the ASSIST substance-specific score and prior
substance use treatment utilization.
3. Assessing the capacity of the ASSIST substance-specific score to serve as a predictor of
future treatment utilization within one year.
Aim 1:
Characterization of the sample involved assessing the differences between subjects who were
identified as substance users by the ASSIST versus those who were identified by another
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method. Odds Ratios were calculated comparing the odds of entry to substance use treatment
within one year for those identified on the ASSIST versus those who were not identified in this
way. All ORs were calculated using logistic regression. These estimates were adjusted for
ASSIST substance-specific score, age, gender, race, ethnicity, number of prior substance use
treatment episodes, number of prior mental health treatment episodes, and number of positive
ever-use substance categories on the ASSIST. Further comparisons between substance users by
the ASSIST versus those who were identified by another methods were completed using t tests
and chi-squared tests, where appropriate.
This section of the study also involved a targeted analysis of the sample indicating opioid
use, specifically assessing non-medical prescription opioid use versus heroin use. Comparisons
of each three groups (prescription opioid users, heroin users, and users of both) were completed
using t-tests and chi-square tests; each category being compared to a combination of the other
two. Logistic regression models were found to compare the odds of entry to treatment within one
year from each group against the remaining two groups. These logistic regression models
adjusted for the log of the number of prior substance use treatment episodes, whether or not the
subject was identified via the ASSIST, the log of the ASSIST Lifetime use score, age, gender,
race, ethnicity, and the log of the number of prior mental health treatments. The results of these
analyses were odds ratios for each of the three categories with 95% confidence intervals.
Additionally a time trend analysis was conducted using a linear regression model.
Aim 2:
Assessing the relationship between the ASSIST substance-specific score involved several
statistical models. Characteristic comparisons between substance users with and without a
recorded prior substance use treatment episode were done by t tests and chi-square tests, as
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appropriate. Rate ratios, indicating the relative increase in prior treatment utilization incidence
for every 10 points on the ASSIST substance-specific score, were calculated by multivariable
Poisson regression models. These models were adjusted for the subjects ASSIST identification
status, the log of the ASSIST Lifetime use score, age, gender, race, ethnicity, the log of the
number of prior mental health treatments, and in the case of Opioids, the specific category of
Opioid use reported (prescription opioid users, heroin users, and users of both). These Poisson
models were adjusted for overdispersion using the method described by Breslow (1984)26.
Aim 3:
The evaluation ASSIST substance-specific score as a predictor of entry to substance use
treatment within one year also involved several statistical models. Unadjusted odds ratios
comparing the ASSIST scores of those who did go on to treatment to those who did not utilized
logistic regression, while the adjusted odds ratios were calculated from multivariate logistic
regression. These later models adjusted the Odds ratio by the log of the number of prior
treatments, whether or not the subject was identified via the ASSIST, the log of the ASSIST
Lifetime use score, age, gender, race, ethnicity, the log of the number of prior mental health
treatments, and in the case of Opioids, the specific category of Opioid use reported. Comparisons
of these characteristics between those who went on to treatment within one year versus those
who did not were conducted via chi-square and t-tests as appropriate.
Comparison between different risk categories of odds of entry to treatment within one
year were developed in a similar way using multivariable logistic regression, adjusting for the
same variables. For these analyses the comparison category was always the ‘low’ risk category.
Comparisons of risk categories by percent going on to treatment within one year were conducted
using chi-square analysis.
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A target reshuffling technique was used to assess variable importance in the multivariable
logistic regression modeling ASSIST score and one-year entry to treatment among opioid users.
The multivariable logistic regression was bootstrapped while systematically reshuffling each
variable in the model in order to determine the degree to which re-shuffling of this variable
reduced the final adjusted pseudo-R2 values; this allows an approximation of the degree to which
each variable contributed to the final model-fit, and thus an approximation of its utility for
prediction of one-year entry to treatment.
Finally, several findings from this section of the study were identified, and E-Values
were calculated for these results along with lower 95% confidence intervals, in order to
contextualize the possibility of potential unaccounted confounding effects. These values were
calculated using the methods described in by VanderWeele and Ding27.

RESULTS
Sample Characteristics, validity of the ASSIST for identification of substance users, and
related sample characteristics

Substance
Opioid
Alcohol
Crack/Cocaine

n
%
n
%

ID
Method
ASSIST
2067
85%
17999
99%

Drug Type
893
37%
1178
6%

Diagnosis
903
37%
1066
6%

TOTAL
2427

n
%

4541
94%

979
20%

847
17%

4847

Table 2-Identification methods for three substance categories

18266
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Of 28,637 patient records 2,427 were identified as having ever used non-medical opioid
or heroin. 18,266 alcohol users were identified as well as 4,847 users of cocaine or crack.
Patients were identified by three possible means – by any positive indication on the ASSIST for
that substance, by a clinical diagnosis in the DMHAS treatment record indicating use of that
substance, or by an appearance of that substance on the patient’s primary, secondary, or tertiary
reported drug type indicator. Table 2 shows the number and percentage of patients identified via
each method. Throughout this study ‘Post treatment’ refers to a record of a substance use
treatment episode which occurred within one year from the ASSIST screening date.
Of note are those patients who did not have a positive indication on the ASSIST while
having a positive indication via drug type or diagnosis. For alcohol and cocaine/crack this group
was only 1% and 6% of the total number of users, respectively, but for opioids 15% of those
identified failed to indicate lifetime use on the ASSIST while having a positive diagnosis or drug
type indicator. Figure 1 shows three Euler diagrams illustrating the proportionality of these

Figure 1-Visual representation of identification method for three substance categories

identification methods for each substance category, illustrating generally stronger crossover
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between diagnosis and clinically indicated drug type than for positive ASSIST identification with
either of these two others. These results suggest that respondents are more likely to admit to
alcohol or cocaine use than opioids when screened via the ASSIST.
Patients who were positively identified via clinical measures (Drug type or diagnosis),
but were unidentified via the ASSIST will be referred to here as non-ASSIST patients. These
Opioids
1 year post Treatment adjusted
OR
Mean # of prior SA treatments
Mean Age
Percent Male
Percent Hispanic
Percent White
Alcohol
1 year post Treatment adjusted
OR
Mean # of prior SA treatments
Mean Age
Percent Male
Percent Hispanic
Percent White
Crack/Cocaine
1 year post Treatment adjusted
OR
Mean # of prior SA treatments
Mean Age
Percent Male
Percent Hispanic
Percent White

ASSIST- NoID
ASSIST
0.19
5.35
44.28
63.50%
34.30%
56.17%
ASSISTID
0.06

5.19
9.52
41.6
58.60%
28.90%
56.39%
NoASSIST

1.11
43.99
41.77%
46.14%
41.17%
ASSISTID

15.47
9.43
43.06
61.50%
18.72%
49.44%
NoASSIST

0.13
3.62
46.54
58.56%
34.05%
49.33%

7.66
9.41
41.65
59.15%
31.70%
49.35%

p(adj)

Power

0.000

100%

0.000
0.000
0.794
0.026
0.794

100%
100%
5%
70%
6%

patients showed different
characteristics than those
who were identified via
the ASSIST. These
differences are shown in

p(adj)

Power

0.000

100%

0.000
0.462
0.000
0.000
0.243

100%
11%
100%
100%
23%

adjusted for confounding

p(adj)

Power

Hochberg False

0.000

100%

Discovery Rate

0.000
0.000
0.651
0.367
0.704

100%
100%
8%
20%
9%

Table 3-Characteristics of ASSIST-identified and ASSIST non-identified subjects by
substance category

Table 3 with p-values

and multiple comparisons
by the Benjamini and

controlling procedure.
Among opioid,
alcohol, and
crack/cocaine users there

were significant differences in the odds of entry to treatment within 1 year, with those who failed
to be identified on the ASSIST consistently showing higher odds of entry to treatment after
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controlling for potential confounding factors such as number of prior treatments, ASSIST
substance-specific score, ASSIST lifetime substance use score, and other demographic factors.
Among opioid users there were also differences between users of prescription opioids,
heroin users, and those who used both substance categories. Figure 2 shows the percentage of all
opioid users who fell into the prescription opioid, heroin, or heroin and prescription opioid

Figure 2-Trends in Opioid use over 35 month study period

categories for each month of the study period, along with a trend line and standard error. A weak
trend was detected for the proportion of prescription opioid users per month, but this was not
statistically significant (p=.639). A moderate downward trend was detected for the proportion of
heroin-only users (p=.001), and a moderate upward trend was detected for the proportion of both
prescription opioids and heroin users (p=.009). These results suggest that while heroin-only users
typically made up a greater proportion of all opioid users, over the course of the study period
more of these heroin users also reported use of prescription opioids. While these trends may
represent national or regional historical changes, sampling bias cannot be ruled out as an
explanation.
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Opioid Type

n

%
total

A) Rx Only
399 16.44%
B) Heroin Only 1276 52.57%
C) Rx & Heroin 752 30.98%

Mean ASSIST
Score (+ID Only, 0
Scores Excluded)
6.12
7.22
9.13

Mean Prior SU
treatment
records
1.89
6.44
7.34

Post Screening
Treatment aOR with
95%CI
.21 (.13 -- .32)
.8 (.64 – 1.01)
2.33 (1.86—2.92)

Table 4-ASSIST Scores, Prior treatments, and Odds Ratio of Post Treatment for three categories of Opioid use

Table 4 shows additional differences between these categories of Opioid use. Mean
ASSIST substance-specific scores were found by excluding all opioid users who had substancespecific scores of zero, excluding all users not identified by the ASSIST. For mean prior
substance use treatment records, values for each category were compared to other categories

Opioid type

A) RX Only
B) Heroin Only
C) RX & Heroin
p < .05
[AvB,BvC,AvC]

Mean
age

%
Male

%
White

%
Hispanic

% non
ASSIST
ID

Mean prior
MH
Treatment
records

ASSIST
Lifetime
Score28

37.9
47.6
40.8

55.9%
65.6%
61.7%

59.2%
47.7%
69.2%

32.6%
40.0%
22.9%

3.3%
17.9%
15.8%

1.73
2.69
2.64

5.98
4.74
4.40

Y,Y,Y

Y,N,N

Y,Y,Y

Y,Y,Y

Y,N,Y

N,N,N

Y,N,Y

Table 5-Characteristic Differences between three opioid use categories

independently, and all categories were found to be significantly different with all p values below
.0001. For a mean ASSIST score, however, prescription-only user scores were not found to be
significantly different from heroin-only user scores. For calculation of adjusted post-treatment
odds ratios, the comparison group was in each case the other two categories (see note 27).

Additional characteristics were found to be different among these three categories, as
shown in Table 5. Here characteristics for each opioid type were statistically compared
individually against each other opioid type. For example, the sample of prescription-opioid-only
users (‘A’) which was 55.9% male, was found to be significantly different than the sample of
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heroin-only users (‘B’) which was 65.6% male, but it was not found to be significantly different
than the sample of prescription-and-heroin users (‘C’), which was 61.7% male. Nor was ‘B’
significantly different from ‘C’ at the p < .05 level. Thus in Table 5 under ‘% Male’ we see
‘Y/N/N’ indicating that the ‘A’ versus ‘B’ comparison was statistically significant, but the the
‘B’ versus ‘C’ and the ‘A’ versus ‘C’ comparisons were not. These differences in statistical
significance suggest a complex relationship between opioid type and several of these
characteristics. For instance, no statistically significant difference was found between the
percentage of users which failed to be identified by the ASSIST among the heroin-only and the
prescription-and-heroin users, but both of these groups were found to have a statistically
significant higher percentage than the prescription-only group. This suggests that heroin use
affects the ability of the ASSIST to identify opioid users more than prescription opioid use.
Other important characteristic differences include age, where prescription opioid users were
found to be younger than heroin and prescription-and-heroin users, and heroin-only users were
found to be older than the other two categories. Statistically significant racial and ethnic
differences were also observed, with heroin-only users most likely to identify as Hispanic and
least likely to identify as white, while prescription-and-heroin users were least likely to identify
as Hispanic and most likely to identify as white. No statistically significant differences were
found among the number of recorded prior mental health treatments. It was found that
prescription-only opioid users reported lifetime ever-use of more substance categories than
heroin-only or prescription-and-heroin users.
Assessing the relationship between the ASSIST substance-specific score and prior
substance use treatment utilization.
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For opioids, alcohol, and cocaine/crack, differences in characteristics were also found
between those who had prior substance use treatment, those who did not, and those who were
within the highest decile number of prior treatment use. Table 6 shows some of these
characteristic differences, and also shows the mean ASSIST substance-specific score for each
group. All sample size values in this table exclude subjects who failed to be identified via the
ASSIST. Mean ASSIST scores are presented excluding scores of 0 (indicating that they were not
identified by the ASSIST), and also including these scores. The mean ASSIST scores excluding
the 0 scores represent the ASSIST scores of those who did and did not have prior substance use
treatment episodes. The mean ASSIST scores including all 0 scores represent what would
actually be observed from the perspective of the provider without knowledge of who the ASSIST
failed to identify.
While many of these characteristics appeared significantly different in the case of alcohol
and cocaine/crack, only the mean ASSIST substance-specific score was found to be a statistically
significant indicator of prior substance use treatment for opioids. More generally, those who had
prior treatments in all categories were usually more likely to be male, younger, and white, while
they were usually less likely to be Hispanic. For alcohol and cocaine/crack
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Opioids

Prior Substance Use Treatments
90th
Percentile
(17+) n=139

Adjusted
p value
(None vs
90th%)

Power

74%

9.29

.004

89%

<.001

100%

5.1

<.001

100%

43.52

0.055

62%

43.42

0.164

29%

59.30%

64.30%

0.055

62%

65.60%

0.453

39%

Percent Hispanic

36.10%

32.40%

0.1

42%

22.90%

0.001

97%

Percent White

53.80%

57.20%

0.137

32%

57.70%

0.658

17%

Adjusted
p value
(None vs
90th%)

N= 1230

Adjusted p
value (None vs
1+)

None

1 or More

n=309

n=921

6.8

8.13

.006

2.9

4.41

44.72

Percent Male

Comparison
Mean ASSIST
Score
(Scores>0)
Mean ASSIST
Score (All)
Mean Age

Alcohol

Power

Prior Substance Use Treatments

N= 17999

None

1 or More

Comparison

n= 14349

Mean ASSIST
Score
(Scores>0)

n= 3650

Adjusted p
value (None vs
1+)

Power

90th
Percentile
(3+) n= 1843

1.84

4.17

<.001

100%

4.85

<.001

100%

Mean ASSIST
Score (All)

1.83

3.9

<.001

100%

4.38

<.001

100%

Mean Age

44.26

42.93

<.001

100%

43.92

0.21

16%

Percent Male

36.90%

61.00%

<.001

100%

63.50%

<.001

100%

Percent Hispanic

49.80%

30.70%

<.001

100%

25.50%

<.001

100%

Percent White

39.60%

47.50%

<.001

100%

49.50%

<.001

100%

Adjusted
p value
(None vs
90th%)

Cocaine/Crack

Power

Prior Substance Use Treatments

N= 4541

None

1 or More

Comparison

n=2224

Mean ASSIST
Score
(Scores>0)

n=2317

Adjusted p
value (None vs
1+)

Power

90th
Percentile
(12+) n= 439

2.37

4.18

<.001

100%

5.62

<.001

100%

Mean ASSIST
Score (All)

2.35

3.72

<.001

100%

4.76

<.001

100%

Mean Age

47.78

44.9

<.001

100%

43.66

<.001

100%

Percent Male

55.20%

61.40%

<.001

99%

62.20%

0.086

81%

Percent Hispanic

39.40%

29.10%

<.001

100%

22.60%

<.001

100%

Percent White

48.60%

50.00%

0.358

15%

54.80%

0.012

71%

Power

Table 6-Characteristics of subjects by number of prior substance use treatment episodes

characteristic trends appeared largely consistent for those without prior treatments, those with
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one or more prior treatments, and those with a number of prior treatments in the top decile.
Alcohol users with a number of prior treatments in the top decile, for instance, were
more likely to be male than those with any number of prior treatments, who were much more
likely to be male than those with no prior treatments. These trends were also largely consistent
among opioid users, but most of these differences were not statistically significant. For each
substance category, the ASSIST substance-specific score was found to be different for each of
these groups, generally increasing with the number of prior treatments, and these differences
were highly statistically significant.
Substance Category Adj Rate Ratio per 10 score
95% CI
p value Adjusted Psuedo-R2
Opioids
1.23
(1.13-1.33) <.001
0.21
Alcohol
1.79
(1.57-1.99) <.001
0.24
Cocaine/Crack
1.88
(1.75-2.01) <.001
0.16
Table 7-Adjusted Rate Ratios per increase of 10 substance-specific ASSIST score by substance category

In order to establish the efficacy of the ASSIST substance-specific score for imputing the
number of prior treatments, a Poisson regression was performed for each of the substance
categories. Table 7 shows the results of these Poisson regressions in the form of the adjusted rate
ratio for every increase of 10 points on the ASSIST substance-specific score. These values
represent the relative incidence rate of prior treatment for every 10 point increase in the ASSIST
substance-specific score. For example, for every increase of 10 points on the ASSIST substancespecific score for opioids, the incidence rate of prior treatment increases by 23% (95%
confidence interval: 13% to 33%), and including adjustment for possible confounding variables,
this model accounts for about 21% of the total variance in prior treatment incidence. Looking
back to table 7, we see that these results indicate that holding the substance-specific score
constant, and adjusting for a number of covariates, cocaine/crack users have a higher relative rate
of substance use treatment than alcohol or opioid users, and that opioids had the lowest relative
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rate of prior substance use treatment. This follows from the fact that adjusted rate ratios for
cocaine/crack were found to be higher than alcohol and opioids, and that opioids had the lowest
rate-ratios of the three.
Assessing the capacity of the ASSIST substance-specific score to serve as a predictor of
future treatment utilization within one year.
For each of the three substance categories evaluated, there were significant differences
between subjects who entered treatment within one year and those who did not. Table 8 shows
these differences with associated p values adjusted for all other variables as well as multiple
comparisons. For mean ASSIST substance-specific score comparisons, only those who
Opioids

Mean ASSIST Score
(+ASSIST ID only)
Mean Age
% ASSIST-ID
% Male
% White
% Hispanic
ASSIST Lifetime
Score
# Prior MH treatments
# Prior SU treatments

Alcohol

Post
Treatment

No Post
Treatment

n=650

n=1777

7.52

3.88

<.001

40.87

44.98

66.77%

Crack/Cocaine

Post
Treatment

No Post
Treatment

Post Tx

No
Post Tx

n=966

n=17300

n=794

n=4053

100%

5.48

2.16

<.001

100%

5.27

<.001

100%

40.99

44.14

<.001

100%

91.90%

<.001

100%

85.40%

99.27%

<.001

66.31%

61.51%

0.004

86%

64.70%

40.76%

59.08%

55.15%

0.624

10%

51.44%

30.46%

34.61%

0.681

7%

5.39

5.91

0.140

2.93

2.37

10.39

4.35

p(adj)

Power

p(adj)

Power

P (adj)

Power

2.99

<.001

100%

41.81

47.10

<.001

100%

100%

77.96%

96.77%

<.001

100%

<.001

100%

64.99%

57.29%

<.001

99%

40.72%

0.175

28%

53.27%

48.56%

0.872

5%

27.64%

46.75%

<.001

100%

27.96%

35.06%

0.007

78%

37%

4.64

2.57

<.001

100%

5.22

4.80

0.044

56%

0.681

8%

2.71

0.82

0.577

10%

3.12

2.02

0.879

6%

<.001

100%

8.84

0.81

<.001

100%

10.13

2.78

<.001

100%

Table 8-Characteristics of subjects who did and did not go on to treatment within one-year by substance category

were identified via the ASSIST were included. While there are a number of significant
differences identified between those who did and did not go on to treatment within one year, a
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Substance

Unadjusted
OR/10

Opioids
Alcohol
Cocaine

1.30
1.98
1.52

29

Unadjusted
psuedo-R2
0.01
0.03
0.01

30

aOR/10
1.38
1.53
1.43

aOR
95%CI

Adjusted psuedoR2 (r)

1.23 - 1.54
1.39 - 1.66
1.25 - 1.60

0.21 (r=.45)
0.35 (r=.59)
0.24 (=.49)

Table 9-Odds Ratios of one-year entry to treatment for every 10 points on the ASSIST substance-specific score

few are of particular note. Mean ASSIST substance-specific scores were significantly higher for
those who had a post-ASSIST treatment admission than for those who did not, but this difference
was greatest for opioid users. Very similar age differences for treatment versus no-treatment
were found across each substance category, though crack/cocaine users tended to be older. The
ASSIST lifetime score only attained significance for alcohol users. Interpreting the ASSIST
Lifetime score as a surrogate measure for poly-substance use, this result suggests that some of

Figure 3-Adjusted Odds-ratios for each ASSIST score category compared to the ‘Low’ category where outcome is entry into
treatment within one year

the treatment episodes for this category may have been for substances other than alcohol. The
number of prior treatments differed among those who did and did not go on to treatment, but the
differences in prior mental health treatments was smaller and not statistically significant, while
the differences in prior substance use treatments were larger and highly statistically significant.
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In order to determine the utility of the ASSIST substance-specific score as a predictor of
entry to treatment within one year, a multivariate logistic regression was run. Results for this
analysis are shown in table 9, where Odds ratios of entry to treatment are shown for every
increase of 10 points on the ASSIST substance-specific score. Additional analyses were
conducted examining the ASSIST substance-specific score categories (High, Moderate-High,
Opioids
Comparison
Mod-High vs High
Mod-High vs ModLow
Mod-High vs Low
High vs Mod-Low
High vs Low
Mod-Low vs Low
Alcohol
Comparison
Mod-High vs High
Mod-High vs ModLow
Mod-High vs Low
High vs Mod-Low
High vs Low
Mod-Low vs Low
Cocaine/Crack
Comparison
Mod-High vs High
Mod-High vs ModLow
Mod-High vs Low
High vs Mod-Low
High vs Low
Mod-Low vs Low

%Post
First
Category
45.45%

%Post
Second
Category
49.32%

45.45%

Moderate-Low, and
Adjusted p

Power

0.831

7%

25.21%

0.010

100%

45.45%
49.32%
49.32%
25.21%

25.94%
25.21%
25.94%
25.94%

0.010

100%

<.001

100%

<.001

100%

0.831

6%

%Post
First
Category
26.58%

%Post
Second
Category
26.58%

Adjusted p

Power

0.878

5%

26.58%

14.15%

0.001

84%

category for subjects

26.58%
27.50%
27.50%
14.15%

4.79%
14.15%
4.79%
4.79%

<.001

100%

who scored in the

0.006

84%

<.001

100%

<.001

100%

Low) as predictors of
one-year entry to
treatment. Figure 3
shows the adjusted
odds ratios with 95%
confidence intervals
of each score

‘Low’ category. With
the exception of the

%Post
First
Category
37.21%

%Post
Second
Category
43.75%

37.21%
37.21%
43.75%
43.75%
40.24%

‘Moderate-Low’

Adjusted p

Power

0.848

10%

category for opioids,

40.24%

0.848

6%

odds ratios appear

15.49%
40.24%
15.49%
15.49%

0.001

100%

0.848

7%

<.001

100%

<.001

100%

Table 10-Multiple Comparisons of unadjusted percentage entering treatment within one year
for three substance categories

elevated over ‘Low’
for every category,
but differentiation
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between these categories appears poor. As the pseudo-R2 values in Table 8 show, the unadjusted
models involving only the ASSIST substance-specific score as a predictor of one-year entry to
treatment accounted for a very small percentage of total variance, while the models incorporating
other factors in addition to ASSIST score (see note 30) accounted for much more of this
variance. Table 10 shows the unadjusted percentages of one-year entry to treatment for each
category comparison, with p values adjusted for multiple comparisons, for each substance
category evaluated. Here differentiation between substance-specific score categories appears
good.
In order to assess relative variable importance within the logistic regression model, a
post-hoc target reshuffling method was utilized. The results of this process for opioids are shown
in Figure 4. These results suggest that the most predictive factors among those evaluated in the

Figure 4-Approximations of variable importance for prediction of one-year entry to treatment among opioid users

model were the number of prior substance use treatments (‘log priors’), followed by the
ASSIST–ID status of the subject, what kind of opioid they used (prescription opioids, heroin, or
both), followed by the age of the subject, followed by the ASSIST substance-specific score.
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Factors such as gender, race, ethnicity, the ASSIST Lifetime score, and the number of mental
health prior treatments, all showed very small predictive value. The value on the y-axis of each
bar corresponds to the estimated loss on the psueduo-R2 metric of the whole model by removal
of that variable. For example, removing the ‘ASSIST_ID_Status’ variable, which represents
whether or not the subject was identified via the ASSIST, reduced the psueduo-R2 metric of the
model from .21 to about .19.
Discussion
The results of this study indicate that the ASSIST is effective for predicting one-year
entry to treatment and for estimating prior treatment utilization for users of prescription opioids,
alcohol, and cocaine/crack in this multi-year state-wide sample.
Not all of those in the study could be identified as users of opioids, alcohol, or
cocaine/crack via the ASSIST, and many subjects were rather identified by clinical indicators
such as diagnosis. Proportionally, this appeared to be a much stronger effect among opioid users
than alcohol or cocaine/crack users (85% identified versus 99% and 94%), however the true
proportions may be lower than these estimates, as not all subjects had associated clinical
information. Nevertheless, differences were observed between those who were and were not
identified via the ASSIST. Entry to treatment within one year appeared strongly associated with
failure to be identified on the ASSIST for all substance categories evaluated, even after adjusting
for prior substance use treatment utilization, ASSIST score, and other variables. The reason for
this difference is unclear, though there are a number of possible explanations. Those who deny
their substance use on the ASSIST may have a more severe substance use disorder. It is also
possible that this is a reflection of the implementation of the ASSIST in the primary care setting.
This result may also be a result of the brief intervention portion of the SBIRT program, which
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may have reduced the need for substance use treatment for those who scored within the
Moderate-Low to Moderate-High range on the ASSIST substance-specific score. None of these
explanations individually appear to completely explain the stark difference in adjusted odds
ratios shown in Table 2, but some combination of them may do so. An additional question
concerns the reason for this failure of identification on the ASSIST, especially among opioid
users where about 15% failed to be identified. One possible explanation is the so-called
phenomenon of ‘doctor shopping’ whereby non-medical prescription opioid users deny use
status in order to obtain prescriptions for opioid from providers. The results from Table 4 suggest
that this is not the case for this sample. Here subjects who only used prescription opioids were
significantly more likely to be identified via the ASSIST than those who used heroin only or both
heroin and prescription opioids. It appears that those opioid users who failed to be identified on
the ASSIST were more likely to use heroin, were less likely to be Hispanic, had higher prior
substance use treatment utilization, and were younger than those who were identified on the
ASSIST.
There may be alternative explanations for these results. Subjects may have failed to
identify lifetime use of a substance if they were presently using a medication intended to treat
their substance use disorder, such as methadone. Alternatively, this result could be a reflection of
the subjects’ readiness for change or motivation. It is possible that subjects seeking to deny
substance use involvement are in fact more likely to have higher treatment utilization. More
research is required to address this topic.
Several trends were identified in the analysis of opioid use by opioid type. Most of the
subjects in the study used only heroin but the proportion of heroin-only users appeared to shrink
over the course of the study, while the proportion of heroin-and-prescription opioid users grew at
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approximately the same rate. The reason for this shift is unclear, but it appears to reflect ongoing
historical trends during this time indicating greater proportions of heroin user reporting
prescription opioid use prior to heroin use.31
Use of both prescription opioids and heroin appeared to be significantly associated with
higher treatment utilization, both in terms of number of prior treatments and odds of entry to
treatment within one year. Given the significant age differences within the three categories,
along with the growing proportion of subjects reporting both heroin and prescription opioids
over the course of the study period, it appears possible that this is representative of a ‘graduation’
effect, and a possible difference from the cohort of heroin-only subjects. On this interpretation
the sample appears to show prescription opioid users as younger, more equally male and female,
mostly white, with lower use disorder severity (indicated by significantly lower ASSIST scores),
more poly-substance use (indicated by the significantly higher ASSIST Lifetime score), low
prior substance use treatment utilization, and low probability of entry to treatment within one
year. Under this ‘graduation’ view, some users of prescription opioids may go on to also use
heroin. In particular these users are associated with higher substance use disorder severity and
markedly greater treatment utilization, as well as a greatly increased odds ratio of entry to
treatment within one year. Those who ‘graduate’ on to heroin are more likely to be white and
male, and are less likely to be Hispanic. These users are also significantly more likely to fail to
be identified on the ASSIST than those who use only prescription opioids.
Several of these results indicate that the ‘graduation’ hypothesis may fail to explain these
results. Those who use both prescription opioids and heroin have significantly lower lifetime
poly-substance use scores as indicated by the ASSIST Lifetime score. While this may be
reconciled with a ‘graduation’ effect by taking into consideration the significantly higher
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percentage failing to be identified on the ASSIST, it is more difficult to reconcile with the trends
identified over the study period. These trends indicated fewer heroin-only users over the course
of the study period, as well as an increased percentage of subjects reporting both prescription
opioids and heroin, but the proportion of prescription opioid only subjects did not appear to
fluctuate. Under the hypothesis that prescription-only users were ‘graduating’ to heroin use, we
would expect to see a reduction in prescription-only subjects over the course of the study, given
an increase in users of both prescription opioids and heroin. These results suggest that the socalled ‘graduation’ hypothesis is unlikely to be the sole explanation for the differences between
opioid users who use prescription opioids, heroin, or both.
Results assessing prior treatment utilization for different substance categories suggest that
the ASSIST score is effective as an indicator of prior treatment utilization. Despite failure to
achieve statistical significance and/or inability to obtain sufficient power for the given sample
sizes across all comparisons, several trends in prior treatment utilization appeared within the
sample. Treatment utilizers generally appeared to be younger, and were more likely to be male,
white, and non-Hispanic. In regards to age specifically, statistical significance at the 90%
utilization level was only achieved for crack/cocaine users. This result might reflect a trend
towards cocaine/crack users entering treatment at an earlier age, or it could alternatively
represent an increased frequency of treatment utilization within a similar period of time.
While it may have been due to a smaller sample size, demographic differences between
opioid users who did and did not utilize substance use treatment prior to ASSIST screening were
not statistically significant, nor were demographic comparisons between those who did not
utilize treatment and those who were in the top decile of substance use treatment utilization. This
did not appear to be the case for alcohol and cocaine/crack users, where demographic differences
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were detected. Overall, the ASSIST substance-specific score did significantly correlate with
increased prior treatment utilization for all three substance categories and the sensitivity of this
association did appear moderately strong. This was especially the case for cocaine/crack users,
for whom an increase of 10 points on the substance-specific score indicated an 88% higher
incidence of substance use treatment utilization. Effects were similarly strong for alcohol users
who had a comparable 79% increase, but the effect was smaller for opioid users, who only had a
23% higher incidence of treatment utilization for the same increase in ASSIST score. The R2
values for each of these models indicate that while the ASSIST score may be more-or-less
sensitive in association with prior treatment utilization, this score along with demographic
variables included in the model account for only a small percentage of the total variance in
treatment utilization. This was particularly the case for cocaine/crack, where the adjusted model
accounted for 16% of the total variance, but the majority of the variance was also left
unexplained for the alcohol and opioid models. ASSIST scores across all levels of prior
treatment utilization appeared low, especially after inclusion of subjects who failed to be
identified on the ASSIST. Therefore, while the association between ASSIST score and prior
treatment utilization itself appears robust, sensitivity would likely have to improve before it
could be effective for this purpose in a primary care environment.
Unsurprisingly, trends in various characteristic differences between those who did and
did not go on to enter treatment within one year were similar to trends in prior treatment
utilization. All tests for significance of these differences were calculated by controlling for other
variables, including prior treatment utilization. Once again the size of the sample was not always
sufficient to identify a statistically significant difference at the effect sizes observed, but trends
appeared to hold across different substance categories regardless of this lack of statistical power.
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Those who went on to a post-screening treatment within one year had higher ASSIST scores,
were younger, were less likely to have been identified by the ASSIST, and were more likely to
be male, and non-Hispanic. ASSIST Lifetime substance use scores tended to be higher among
those who went on to treatment within one year, suggesting higher rates of poly-substance use,
though this effect was not significant among opioid users. This difference was greatest among
alcohol users, which is not surprising given that the entry to substance use treatment need not
have been for reasons relating to alcohol. For each substance category, prior substance use
treatment utilization was much higher among those who would go on to enter treatment within
one year.
After controlling for all of these factors, including prior treatment utilization, the ASSIST
substance-specific score was found to be significantly associated with entry to treatment within
one year. Indeed, mean ASSIST scores for those who went on to treatment were 1.75 to 2.5
times higher than the mean scores of those who did not go on to treatment. Several other results
complicate this finding. As noted, subjects who went on to treatment were significantly less
likely to be identified on the ASSIST. This difference was controlled for in the model associating
ASSIST score and entry to treatment, but it does raise concerns regarding the efficacy of the
ASSIST for prediction of entry to treatment given that a clinical setting would not necessarily
have access to previous substance use diagnoses or clinical records from prior SU treatment
episodes.
Examining the sensitivity of the ASSIST score for predicting entry to treatment reveals a
complex picture. A simple unadjusted model finds that for every 10 points on the ASSIST score
an opioid user has 30% greater odds for entry to treatment within one year. This effect was
stronger for alcohol users at 98% increased odds, and 52% for cocaine users. The R2 values for
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these models reveal that they are accounting for a very small percentage of the total variance,
indicating that by itself, substance use severity as captured by the ASSIST score accounts for
only a small amount of the reason these users are entering treatment. Adjustment of these models
involved incorporation of other known factors. In the case of alcohol and cocaine odds ratios
were reduced, suggesting that the ASSIST score in the unadjusted model was in some way
functioning as a surrogate measure for these other known factors; probably prior substance use
treatment utilization given the results of Table 6. The OR for opioid increased however,
suggesting that for these users the association of the ASSIST score with entry to post treatment
was being masked by confounding factors.
While the raw ASSIST score was found to be predictive of entry to treatment within one
year, in a clinical setting risk categories are more commonly used. The association between
ASSIST score category and risk of one year entry to treatment showed inconsistent
differentiation within the three substance categories examined. All alcohol and cocaine users
who fell into the ‘high’, ‘moderate high’, or ‘moderate low’ were more likely than users who fell
into the ‘Low’ category to go on to substance use treatment within one year, but no significant
difference was found between these groups separately. Among opioid users only those who fell
into the ‘high’ or ‘moderate-high’ categories were found to have significantly elevated ORs in
comparison to those who fell into the ‘low’ category, and differences between these two
categories were not found to be significant.
While adjusted models such as these are important for isolating the association of the
ASSIST score and one-year entry to treatment, they may be less interpretable in a clinical
setting. For these purposes we might wish to look at the unadjusted figures to understand the
differentiation of score categories for prediction of entry to treatment. These results tell a
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different story. Among opioid users, differentiation among ‘high’ and ‘moderate-high’ scoring
users appears poor, along with differences between ‘low’ and ‘moderate-low’ users. Power was
insufficient in either of these cases to demonstrate this lack of differentiation as significant, but
the simple percentage difference between each set of categories is quite small. These results
suggest that for this group it might be more beneficial to simply categorize opioid patients as
‘high’ or ‘low’ risk for the purposes of predicting entry to treatment. Among alcohol users
differentiation appeared strong for all categories except for ‘High’ and ‘Moderate-High’
suggesting that these groups may have similar degrees of treatment utilization. Cocaine users
showed a less straightforward pattern with strong differentiation only with the ‘Low’
categorization, suggesting that the other groups showed similar treatment utilization patterns,
though this could have been due to insufficient power to detect the effect sizes here, which were
in some cases moderate.

Substance
Opioids

Reported Measure
aOR/10
'High' vs. 'Low' aOR
'Mod-High' vs 'Low' aOR
Alcohol
aOR/10
'High' vs. 'Low' aOR
'Mod-High' vs 'Low' aOR
Cocaine/Crack
aOR/10
'High' vs. 'Low' aOR
'Mod-High' vs 'Low' aOR

Reference
Table 9
Figure 3
Figure 3
Table 9
Figure 3
Figure 3
Table 9
Figure 3
Figure 3

Reported OR
1.38
2.80
2.28
1.53
4.16
3.24
1.43
3.19
2.40

E-Value
2.10
5.04
3.99
2.43
7.79
5.93
2.21
5.83
4.23

E-Value (low
95%CI)
1.76
2.66
1.49
2.13
4.01
3.56
1.81
2.66
1.64

Table 11-Selected results and calculated E-Values with confidence intervals

The results of this study suggest that the ASSIST substance-specific score may be an
effective predictor for one year entry to treatment, but these results are limited due to the fact that
subjects received a brief intervention or referral to treatment depending upon these scores. This
intervention could also explain the increased treatment utilization observed by those who scored
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higher on the ASSIST. To better assess this potential confounding effect, Table 11 reports
several of the principal results from this study along with a calculated E-Value for each, as
described in a recent paper by VanderWeele and Ding32. Here the authors describe the E-value as
“a continuous measure of an association’s robustness to potential uncontrolled
confounding…The higher the E-value, the stronger the confounder associations must be in order
to explain away the effect.” For example looking to table 11 we see that the adjusted odds ratio
for an opioid user scoring in the ‘High’ category going on to treatment within one year, as
compared to an opioid user in the ‘low’ category, was 2.8. Here the E-value33 is 5.04 with a
lower 95% CI of 2.66, suggesting that the sum total effect of any confounders which would
explain away this effect would have to have this OR. In this case we know that opioid users
falling into the ‘high’ score category were given a brief intervention and referred to treatment –
in order for the confounding effect of this intervention to account for the observed association,
the effect of this and other confounding effects would have to make users falling into the ‘High’
score category about 166 to 400% more likely to enter treatment within one year than users in
the ‘Low’ score category. This can be difficult to contextualize because few studies so far
evaluated rates of entry to treatment following brief interventions and referral to treatment 34. One
study reported that among 347 opioid users the odds of users reporting willingness to enter
treatment were 57% higher among those who participated in an SBIRT program as compared to
those who did not 35.
While the association of ASSIST score and one year entry to treatment is limited by the
potential confounding effect of brief interventions and referral to treatment, other related results
are less obviously limited by this effect. The identified association between the ASSIST score
and prior treatment utilization for instance would be unlikely to be susceptible to this
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confounding effect, as well as the overall association between past and future treatment
utilization. Differences were also identified in the sensitivity of the ASSIST score category to
prediction of future treatment utilization across separate substance categories. It is possible that
this could indicate a difference in the efficacy or consistency of the applied interventions for
each score category.
Regardless of limitations, these results show that the ASSIST substance-specific score
can indeed be an effective predictor for one year entry to treatment, but this efficacy is relative to
other potential predictors. Figure 4 shows that the ASSIST score is not the most effective
predictor of one-year entry to treatment; the number of prior substance use treatments is the most
important variable for this prediction, followed by whether the subject was identified via the
ASSIST or not, whether the subject used prescription opioids, heroin, or both, the age of the
subject, and then the ASSIST score. Currently both opioid type and ASSIST score are captured
via the ASSIST, but this illustrates the potential utility of asking patients about their prior
substance use treatment utilization. With the exception of ASSIST Identification status, all of the
top 10 predictive variables for one-year entry to treatment could be captured by a screening tool
including the ASSIST, simple demographic questions, and questions regarding the subject’s
history of prior treatment.
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Adam Chess | Page 39

Adam Chess | Page 40

Adam Chess | Page 41

Adam Chess | Page 42

REFERENCES & NOTES

1

Nations, U. (2016). World drug report 2016. New York: United Nations
Opioid Addiction 2016 Facts & Figures. (2016). American Society of Addiction Medicine. Retrieved from
https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf.
3
Rudd, Rose A, et al. “Morbidity and Mortality Weekly Report (MMWR).” Centers for Disease Control and
Prevention, Centers for Disease Control and Prevention, 14 Aug. 2017,
www.cdc.gov/mmwr/volumes/65/wr/mm655051e1.htm.
4
Centers for Disease Control and Prevention. Annual Surveillance Report of Drug-Related Risks and Outcomes United States, 2017. Surveillance Special Report 1. Centers for Disease Control and Prevention, U.S.
Department of Health and Human Services. Published August 31,
2017.https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf
5 Rondinone, N. (2017, January 06). CDC: Connecticut Second In Percent Increase Of Synthetic Opioid Deaths Rate.
Retrieved March 27, 2018, from http://www.courant.com/breaking-news/hc-cdc-fentanyl-overdoses20170105-story.html
6 Whiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2016). Global Burden of Mental, Neurological,
and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. Disease Control
Priorities, Third Edition (Volume 4): Mental, Neurological, and Substance Use Disorders, 29-40.
doi:10.1596/978-1-4648-0426-7_ch2
7 Council of Economic Advisors. (2017). Council of Economic Advisers Report: the Underestimated Cost of the
Opioid Crisis. Retrieved from https://www.whitehouse.gov/briefings-statements/cea-reportunderestimated-cost-opioid-crisis/
8 Wu, L., Zhu, H., & Swartz, M. S. (2016). Treatment utilization among persons with opioid use disorder in the
United States. Drug and Alcohol Dependence, 169, 117-127. doi:10.1016/j.drugalcdep.2016.10.015
9 Jones, C. M., Campopiano, M., Baldwin, G., & Mccance-Katz, E. (2015). National and State Treatment Need and
Capacity for Opioid Agonist Medication-Assisted Treatment. American Journal of Public Health, 105(8).
doi:10.2105/ajph.2015.302664
10 Brewer, D. D., Catalano, R. F., Haggerty, K., Gainey, R. R., & Fleming, C. B. (1998). RESEARCH REPORT A metaanalysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction,
93(1), 73-92. doi:10.1046/j.1360-0443.1998.931738.x
11 Barry, C. L., Epstein, A. J., Fiellin, D. A., Fraenkel, L., & Busch, S. H. (2016). Estimating demand for primary carebased treatment for substance and alcohol use disorders. Addiction, 111(8), 1376-1384.
doi:10.1111/add.13364
12
Babor, T. F., Mcree, B. G., Kassebaum, P. A., Grimaldi, P. L., Ahmed, K., & Bray, J. (2007). Screening, Brief
Intervention, and Referral to Treatment (SBIRT). Substance Abuse, 28(3), 7-30. doi:10.1300/j465v28n03_03
13
Bachhuber, M., Weiner, J., Mitchell, J., & Samet, J. (2016, August 09). Primary Care: On the Front Lines of the
Opioid Crisis. Retrieved December 28, 2017, from https://ldi.upenn.edu/brief/primary-care-front-linesopioid-crisis
14
Goplerud, E., & McPherson, T. L. (2015). IMPLEMENTATION BARRIERS TO AND FACILITATORS OF SCREENING,
BRIEF INTERVENTION, REFERRAL, AND TREATMENT (SBIRT) IN FEDERALLY QUALIFIED HEALTH CENTERS
(FQHCS). Office of Disability, Aging and Long-Term Care Policy.
15
ASSIST Working Group. (2002). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST):
development, reliability and feasibility. Addiction, 97(9), 1183-1194. doi:10.1046/j.1360-0443.2002.00185.x
16
World Health Organization. (2010). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
Manual for use in primary care. Retrieved from http://www.who.int/substance_abuse/publications/assist/en/
17
Humeniuk, R., Ali, R., Babor, T. F., Farrell, M., Formigoni, M. L., Jittiwutikarn, J., . . . Simon, S. (2008). Validation of
the alcohol, smoking and substance involvement screening test (ASSIST). Addiction, 103(6), 1039-1047.
doi:10.1111/j.1360-0443.2007.02114.x
18
Humeniuk, R., & Ali, R. (2006). Validation of the Alcohol, Smoking and Substance Involvement Screening Test
(ASSIST) and Pilot Brief Intervention: A Technical Report of Phase II Findings of the WHO ASSIST Project
(Rep.). WHO ASSIST Project.
2

Adam Chess | Page 43

19

Gryczynski, J., Kelly, S. M., Mitchell, S. G., Kirk, A., Ogrady, K. E., & Schwartz, R. P. (2014). Validation and
performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent
primary care patients. Addiction, 110(2), 240-247. doi:10.1111/add.12767
20
Hides, L., Cotton, S. M., Berger, G., Gleeson, J., Odonnell, C., Proffitt, T., . . . Lubman, D. I. (2009). The reliability
and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode
psychosis. Addictive Behaviors, 34(10), 821-825. doi:10.1016/j.addbeh.2009.03.001
21
Sainz, M. T., Rosete-Mohedano, M. G., Rey, G. N., Vélez, N. A., García, S. C., & Cisneros, D. P. (2016). Validity and
Reliability of the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) in University
Students. Adicciones, 28(1), 19. doi:10.20882/adicciones.786
22
Glass, J. E., Hamilton, A. M., Powell, B. J., Perron, B. E., Brown, R. T., & Ilgen, M. A. (2015). Specialty substance
use disorder services following brief alcohol intervention: a meta-analysis of randomized controlled trials.
Addiction, 110(9), 1404-1415. doi:10.1111/add.12950
23
Babor, T. F., Mcree, B. G., Kassebaum, P. A., Grimaldi, P. L., Ahmed, K., & Bray, J. (2007). Screening, Brief
Intervention, and Referral to Treatment (SBIRT). Substance Abuse, 28(3), 7-30. doi:10.1300/j465v28n03_03
24
Paltzer, J., Brown, R. L., Burns, M., Moberg, D. P., Mullahy, J., Sethi, A. K., & Weimer, D. (2016). Substance Use
Screening, Brief Intervention, and Referral to Treatment Among Medicaid Patients in Wisconsin: Impacts on
Healthcare Utilization and Costs. The Journal of Behavioral Health Services & Research, 44(1), 102-112.
doi:10.1007/s11414-016-9510-2
25
Bernstein, E., Bernstein, J., & Levenson, S. (1997). Project ASSERT: An ED-Based Intervention to Increase Access
to Primary Care, Preventive Services, and the Substance Abuse Treatment System. Annals of Emergency
Medicine, 30(2), 181-189. doi:10.1016/s0196-0644(97)70140-9
26
Breslow, N.E. (1984), Extra-Poisson variation in log-linear models, Applied Statistics, 33, 38–44.
27
Vanderweele, Tyler J., and Peng Ding. “Sensitivity Analysis in Observational Research: Introducing the E-Value.”
Annals of Internal Medicine, vol. 167, no. 4, 2017, p. 268., doi:10.7326/m16-2607.
28
The ASSIST Lifetime score is the summation of question 1 on the ASSIST, where 3 points are assigned for each
substance identified under ever lifetime use. Thus the ASSIST Lifetime score correlates to the number of
substance categories the subject has ever used. Here the scores for users of both prescription and heroin
users were reduced by 3 to adjust for the additional substance category they reported positive ever-use.
29
Adjusted McFadden pseudo-R2 values were used for both adjusted and unadjusted models
30
Models were adjusted for number of prior substance use and mental health treatments on logarithmic scale,
age, gender, race, ethnicity, ASSIST ID status, the logarithm of the ASSIST Lifetime score, and in the case of
Opioids, prescription opioid versus heroin use.
31
Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The Changing Face of Heroin Use in the United States.
JAMA Psychiatry, 71(7), 821. doi:10.1001/jamapsychiatry.2014.366
32
Vanderweele, Tyler J., and Peng Ding. “Sensitivity Analysis in Observational Research: Introducing the E-Value.”
Annals of Internal Medicine, vol. 167, no. 4, 2017, p. 268., doi:10.7326/m16-2607.
33
The E-value is calculated for ORs by taking these ORs as estimates of Risk Ratios (‘RR’) and applying the following
formula for RRs greater than 1; E-value = RR + sqrt(RR x (RR – 1)). This formula is applied to the lower bound
of the confidence interval to determine the confidence interval.
34
Young, M. M., Stevens, A., Galipeau, J., Pirie, T., Garritty, C., Singh, K., . . . Moher, D. (2014). Effectiveness of brief
interventions as part of the Screening, Brief Intervention and Referral to Treatment (SBIRT) model for
reducing the nonmedical use of psychoactive substances: A systematic review. Systematic Reviews, 3(1).
doi:10.1186/2046-4053-3-50
35
Bernstein, J., Bernstein, E., Tassiopoulos, K., Heeren, T., Levenson, S., & Hingson, R. (2005). Brief motivational
intervention at a clinic visit reduces cocaine and heroin use. Drug and Alcohol Dependence, 77(1), 49-59.
doi:10.1016/j.drugalcdep.2004.07.006
36
WHO (2010). The ASSIST Questionnaire Version 3.0 (English Version) [Measurement Instrument]. Retrieved from
http://www.who.int/substance_abuse/activities/assist_v3_english.pdf?ua=1

